JP2024532485A5 - - Google Patents
Info
- Publication number
- JP2024532485A5 JP2024532485A5 JP2024513933A JP2024513933A JP2024532485A5 JP 2024532485 A5 JP2024532485 A5 JP 2024532485A5 JP 2024513933 A JP2024513933 A JP 2024513933A JP 2024513933 A JP2024513933 A JP 2024513933A JP 2024532485 A5 JP2024532485 A5 JP 2024532485A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- region sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163240402P | 2021-09-03 | 2021-09-03 | |
| US63/240,402 | 2021-09-03 | ||
| US202263327700P | 2022-04-05 | 2022-04-05 | |
| US63/327,700 | 2022-04-05 | ||
| PCT/US2022/075846 WO2023034922A2 (en) | 2021-09-03 | 2022-09-01 | Bispecific binding proteins that bind cd137 and a tumor associated antigen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024532485A JP2024532485A (ja) | 2024-09-05 |
| JP2024532485A5 true JP2024532485A5 (cg-RX-API-DMAC7.html) | 2025-09-05 |
Family
ID=85413134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513933A Pending JP2024532485A (ja) | 2021-09-03 | 2022-09-01 | Cd137および腫瘍関連抗原に結合する二重特異性結合タンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240383978A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4395823A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024532485A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240073008A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022337286A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3230426A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023034922A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024008500A (es) * | 2022-01-09 | 2024-08-26 | I Mab Biopharma Co Ltd | Construcciones multiespecíficas y usos de estas. |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2564432A1 (en) * | 2004-04-27 | 2005-11-10 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Human anti-amyloid .beta. peptide antibody and fragment of said antibody |
| JP2011524179A (ja) * | 2008-06-16 | 2011-09-01 | パトリス リミテッド | Lm−1抗体、機能性フラグメント、lm−1標的抗原、ならびにそれらを作製および使用するための方法 |
| CN106459165B (zh) * | 2014-04-01 | 2021-04-20 | 拜恩科技细胞&基因治疗有限公司 | 密封蛋白-6特异性免疫受体和t细胞表位 |
| EP3554544A4 (en) * | 2016-12-16 | 2020-07-29 | Bluefin Biomedicine, Inc. | ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE |
| CN112020516B (zh) * | 2018-03-13 | 2025-01-03 | 塔斯克疗法有限公司 | 用于肿瘤特异性细胞清除的抗-cd25 |
| WO2020191344A1 (en) * | 2019-03-20 | 2020-09-24 | The Regents Of The University Of California | Claudin-6 bispecific antibodies |
| US11261259B2 (en) * | 2019-08-12 | 2022-03-01 | I-Mab Biopharma Us Limited | Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof |
| JP2022545835A (ja) * | 2019-08-28 | 2022-10-31 | ホライゾン セラピューティクス アイルランド デジグネイテッド アクティビティ カンパニー | 甲状腺眼症の治療方法 |
| CA3164996A1 (en) * | 2019-12-20 | 2021-06-14 | Novarock Biotherapeutics, Ltd. | Anti-interleukin-23 p19 antibodies and methods of use thereof |
| PH12022552323A1 (en) * | 2020-03-31 | 2023-12-04 | Chugai Pharmaceutical Co Ltd | Claudin-6 targeting multispecific antigen-binding molecules and uses thereof |
| EP4301784A4 (en) * | 2021-03-02 | 2025-01-01 | NovaRock Biotherapeutics, Ltd. | Antibodies against claudin-6 and uses thereof |
-
2022
- 2022-09-01 CA CA3230426A patent/CA3230426A1/en active Pending
- 2022-09-01 WO PCT/US2022/075846 patent/WO2023034922A2/en not_active Ceased
- 2022-09-01 KR KR1020247008121A patent/KR20240073008A/ko active Pending
- 2022-09-01 US US18/688,630 patent/US20240383978A1/en active Pending
- 2022-09-01 AU AU2022337286A patent/AU2022337286A1/en active Pending
- 2022-09-01 EP EP22865806.8A patent/EP4395823A4/en active Pending
- 2022-09-01 JP JP2024513933A patent/JP2024532485A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wu et al. | Building blocks for bispecific and trispecific antibodies | |
| JP7549961B2 (ja) | 少なくともcd3及びhsaを標的とするヘテロ二量体多重特異性抗体フォーマット | |
| CN107922486B (zh) | 异源二聚体多特异性抗体形式 | |
| JP6669722B2 (ja) | Cd3結合ドメイン | |
| JP2023082067A (ja) | 改良された抗原結合受容体 | |
| RU2355705C2 (ru) | Одноцепочечное цикличное триспецифическое антитело | |
| WO2015063187A1 (en) | Multivalent antigen-binding proteins | |
| JP2023518134A5 (cg-RX-API-DMAC7.html) | ||
| Xiong et al. | Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20× anti-CD3 bispecific diabody | |
| JP2016514676A (ja) | 四価二重特異性抗体 | |
| CN103687879A (zh) | 多价抗原结合fv分子 | |
| CN115066274A (zh) | 三价结合分子 | |
| JP2024001073A5 (cg-RX-API-DMAC7.html) | ||
| JP2025508316A5 (cg-RX-API-DMAC7.html) | ||
| CN113150156B (zh) | 抗tigit抗体及其用途 | |
| JP2024504162A5 (cg-RX-API-DMAC7.html) | ||
| Acheampong | Bispecific antibody (bsAb) construct formats and their application in cancer therapy | |
| JP2025512953A5 (cg-RX-API-DMAC7.html) | ||
| JP2024541476A5 (cg-RX-API-DMAC7.html) | ||
| JP2024546923A5 (cg-RX-API-DMAC7.html) | ||
| WO2021113748A1 (en) | Composition of triaxial antibodies and method of making and using thereof | |
| CN113825772A (zh) | 抗her2亲合体及将其用作开关分子的可切换嵌合抗原受体 | |
| Li et al. | Advancing immunotherapy via multiple immune cells co-engagement | |
| JP2025505611A5 (cg-RX-API-DMAC7.html) | ||
| JP2022550120A5 (cg-RX-API-DMAC7.html) |